“Covid-19” drug treatment criteria for patients At what level to give favipiravir?

issue”Covid-19” medical department Dr. Somsak Ankasil, Director-General of the Department of Medical Services, revealed that the drug treatment criteria for COVID-19 patients are in accordance with the guidelines for medical practice, diagnosis, care and prevention of infection in hospitals. Case of Coronavirus Disease 2019 or COVID-19 for Doctors and Public Health Personnel, Revised Edition, May 18, 2022

Read related news.

– Total number of Covid-19 today: 2,695 more infected, 14 deaths, 4,034 more ATK

– “Covid today” Chonburi province has 209 new infections, excluding ATK 2,833 more.

– “New species of covids” season of BA.4 BA.5 epidemic direction, chance of re-infection

The guidelines for treating patientsCovid-19 This is the 23rd edition which has been modified according to the situation all along. To provide care for COVID-19 patients most efficient

treatment for covid-19

Probable case: those who haveATK test results SARS-CoV-2 was positive and included both symptomatic and asymptomatic confirmed cases. can be divided into groups according to the severity of the disease and risk factors into 4 cases as follows:

1. Patients without symptoms or in good health (Asymptomatic COVID-19)

• provide outpatient treatment by isolating at home (Out-patient with self isolation) or home isolation or at a government facility as appropriate

• Provide symptomatic care at the discretion of the physician. Do not give antiviral drugs such as favipiravir. (favipiravir), as most of them go away on their own.

• May consider giving Andrographis paniculata at the discretion of the physician

2. Patients with mild symptoms no pneumonia No risk factors for severe disease, major comorbid disease and normal lung radiographs (Symptomatic COVID-19 without pneumonia and no risk factors for severe disease).

• may consider favipiravir (favipiravir) should be started as soon as possible.

• If the infection is detected when the patient has symptoms for more than 5 days and the patient has no symptoms or has few symptoms, it may not be Antiviral medication is required. because the patient will heal on his own without complications

3. Patients with mild symptoms Patients with no risk factors but with mild to moderate pneumonia do not need oxygen.

Risk factors for severe disease include:

1) over 60 years of age

2) chronic obstructive pulmonary disease (COPD) (GOLD grade 2 or higher), combined with other chronic lung diseases.

3) Chronic Kidney Disease (CKD) (stage 3 and above)

4) Cardiovascular disease (NYHA functional class 2 and above) including congenital heart disease

5) Stroke

6) Uncontrolled diabetes

7) Obesity (weight greater than 90 kg or BMI 230 kg/m²)

8) Cirrhosis (Child-Pugh class B and above)

9) Low Immunity (a disease that is in the process of receiving chemotherapy or immunosuppressive drugs or corticosteroid equivalent to prednisolone 15 mg/day for 15 days or more

10) HIV-infected with CD. cell count less than 200 cells/m3.

Only one antiviral drug is recommended, which should be started within 5 days of the onset of symptoms to be effective. By considering the following factors:

• Vaccination history
• Contraindications to the drug
• drug-drug interactions
• bed management convenience of medication
• reserve amount of medication

4. Confirmed patients with pneumonia with hypoxia (resting O, saturation <94%, severe pneumonia less than 10 days after symptom onset and receiving oxygen.

• Remdesivir is recommended for 5-10 days depending on clinical symptoms. and should closely monitor the patient’s symptoms

• A corticosteroid is recommended.

Treatment of COVID-19 in pediatric patients younger than 18 years

Information from the Department of Medical Services